Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer

European Journal of Cancer

Volumn 46, Issue 1, 2010, Pages 102-109

  Gerestein, C G ^a,b   Nieuwenhuyzen de Boer, G M ^b   Eijkemans, M J ^a   Kooi, G S ^b   Burger, C W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ALBERT SCHWEITZER HOSPITAL   (Netherlands)

Author keywords

30 Day morbidity; Cytoreductive surgery; Ovarian cancer; Postoperative mortality; Surgical complications

Indexed keywords

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; NETHERLANDS; OPERATION DURATION; OVARY CANCER; PERIOPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SURGICAL MORTALITY; SURGICAL RISK; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INTRAOPERATIVE PERIOD; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NOMOGRAMS; OVARIAN NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71149118997     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.10.017     Document Type: Article

References (39)

1. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 5 (2002) 1248-1259
2. du Bois A., Reuss A., Pujade-Lauraine E., et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer (2009)
3. Allen D.G., Heintz A.P., and Touw F.W. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 16 5 (1995) 349-356
4. Winter III W.E., Maxwell G.L., Tian C., et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26 1 (2008) 83-89
5. Chen S.S., and Bochner R. Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma. Gynecol Oncol 20 2 (1985) 190-195
6. Suzuki M., Ohwara M., Sekiguchi I., and Sato I. Radical cytoreductive surgery combined with platinums-carboplatin and cisplatin chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 9 1 (1999) 54-60
7. Heintz A.P., Hacker N.F., Berek J.S., et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 67 6 (1986) 783-788
8. Eisenkop S.M., Spirtos N.M., Montag T.W., Nalick R.H., and Wang H.J. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47 2 (1992) 203-209
9. Eisenkop S.M., Spirtos N.M., Friedman R.L., et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90 2 (2003) 390-396
10. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., and Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72 3 (1999) 278-287
11. Engelen M.J., Kos H.E., Willemse P.H., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106 3 (2006) 589-598
12. Bristow R.E., and Montz F.J. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 83 1 (2001) 39-48
13. Aletti G.D., Santillan A., Eisenhauer E.L., et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 107 1 (2007) 99-106
14. Piver M.S., and Baker T. The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol 24 1 (1986) 1-8
15. Guidozzi F., and Ball J.H. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 53 3 (1994) 326-330
16. Michel G., De Iaco P., Castaigne D., et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 18 1 (1997) 9-15
17. Gerestein C.G., Damhuis R.A., Burger C.W., and Kooi G.S. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol (2009)
18. Khuri S.F. The NSQIP: a new frontier in surgery. Surgery 138 5 (2005) 837-843
19. Shimizu Y., Kamoi S., Amada S., et al. Toward the development of a universal grading system for ovarian epithelial carcinoma I. Prognostic significance of histopathologic features-problems involved in the architectural grading system. Gynecol Oncol 70 1 (1998) 2-12
20. Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 156 1 (1987) 263-264
21. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 5 (1987) 373-383
22. Khuri S.F., Daley J., Henderson W., et al. The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. Ann Surg 228 4 (1998) 491-507
23. Waljee J.F., Windisch S., Finks J.F., Wong S.L., and Birkmeyer J.D. Classifying cause of death after cancer surgery. Surg Innov 13 4 (2006) 274-279
24. Daley J., Khuri S.F., Henderson W., et al. Risk adjustment of the postoperative morbidity rate for the comparative assessment of the quality of surgical care: results of the National Veterans Affairs Surgical Risk Study. J Am Coll Surg 185 4 (1997) 328-340
25. Steyerberg E.W., Eijkemans M.J., Harrell Jr. F.E., and Habbema J.D. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 19 8 (2000) 1059-1079
26. van Buuren S., Boshuizen H.C., and Knook D.L. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 18 6 (1999) 681-694
27. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 4 (1996) 361-387
28. Van Houwelingen J.C., and Le Cessie S. Predictive value of statistical models. Stat Med 9 11 (1990) 1303-1325
29. Chi D.S., Franklin C.C., Levine D.A., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94 3 (2004) 650-654
30. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103 3 (2006) 1083-1090
31. Venesmaa P., and Ylikorkala O. Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 79 2 (1992) 168-172
32. Alphs H.H., Zahurak M.L., Bristow R.E., and Diaz-Montes T.P. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol 103 3 (2006) 1048-1053
33. Diaz-Montes T.P., Zahurak M.L., Giuntoli II R.L., et al. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol 99 2 (2005) 352-357
34. Cloven N.G., Manetta A., Berman M.L., Kohler M.F., and DiSaia P.J. Management of ovarian cancer in patients older than 80 years of Age. Gynecol Oncol 73 1 (1999) 137-139
35. Vergote I., De Wever I., Tjalma W., et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71 3 (1998) 431-436
36. Vergote I, Trope C, Amant F, et al. EORTC-GCG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC/IV ovarian, fallopian tube and peritoneal cancer. In: 12th Biennal Meeting International Gynecologic Cancer Society. Bangkok, Thailand; 2008.
37. Schwartz P.E., Chambers J.T., and Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 53 1 (1994) 33-37
38. Huober J., Meyer A., Wagner U., and Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol 128 3 (2002) 153-160
39. Janda M., Youlden D.R., Baade P.D., Jackson D., and Obermair A. Elderly patients with stage III or IV ovarian cancer: should they receive standard care?. Int J Gynecol Cancer 18 5 (2008) 896-907